Irazem

Quick links to important sections

Irazem

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Irazem

Property Description
Active ingredient Aripiprazole (INN)
Form Tablet, Oral Solution, Intramuscular Injection
Pharmacological class Atypical Antipsychotic Agent (Third-Generation)
Common purpose Neurochemical stabilization / Emotional equilibrium
Origin Synthetic Compound

Irazem is a trade name for a pharmaceutical product containing the active chemical compound Aripiprazole. This substance is a synthetic small molecule and a single-ingredient product, definitively classified as an atypical antipsychotic agent. The distinction of Aripiprazole, which is clinically recognized as a third-generation antipsychotic, lies in its unique mechanism.

The drug functions primarily as a highly specialized regulator—a partial agonist—at the Dopamine D2 and Serotonin 5-HT1A receptors, while acting as an antagonist at the Serotonin 5-HT2A receptor. This complex, adaptive mechanism ensures the drug can effectively provide dopamine-serotonin system stabilization within the brain, helping to correct underlying imbalances in these key signaling pathways. The general therapeutic goal of this action is to foster overall emotional equilibrium and support the stabilization of behavior.

The active ingredient is made available via both oral and intramuscular administration routes. The various dosage forms include the conventional oral tablet, the orally-disintegrating tablet (ODT), and a dedicated oral solution. For scenarios requiring highly controlled or long-term administration, Irazem is also available as both acute and long-acting intramuscular injections (IM / LAI), providing flexibility in patient management.

Regulatory References

  1. Aripiprazole EPAR Overview

What side effects are possible with Irazem?

Possible side effects and safety information

The safety profile of Irazem, which contains Aripiprazole, is formally documented by government regulatory agencies and classified by frequency and affected physiological systems. Most common adverse reactions, classified as Common (occurring in 1 in 100 to 1 in 10 patients), often involve the Nervous System and Gastrointestinal Disorders. These commonly reported effects include movement disorders like Akathisia (restlessness) and Tremor, as well as central effects such as Insomnia, Somnolence, Dizziness, Headache, and gastrointestinal issues like Nausea and Constipation.

The label defines several Serious Adverse Reactions (SARs) that are monitored, including Neuroleptic Malignant Syndrome (NMS) and potentially irreversible involuntary movements known as Tardive Dyskinesia (TD). Other serious risks involve severe metabolic events like hyperglycemia (high blood sugar) and Cerebrovascular Adverse Reactions (such as stroke), particularly when the medication is used in older adults with dementia-related psychosis, a population associated with an increased risk of mortality.

Safety notes also address specific situations. Orthostatic Hypotension (dizziness upon standing) is noted to be more common at the start of treatment or during dose increases. Furthermore, reports in regulatory documents link the medication to the emergence or intensification of impulse control disorders, such as pathological gambling. The official safety data confirms that all risks are categorized to structure the understanding of the drug's safety profile without providing clinical advice.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Irazem (Aripiprazole) by listing documented clinical manifestations and severe systemic risks. An overdose may present with signs such as somnolence (drowsiness), tremor, and vomiting. More serious documented neurological manifestations include convulsions (seizures), loss of consciousness, and coma. Overdosage is associated with potentially life-threatening outcomes in the cardiovascular system, specifically Tachycardia, hypotension, and significant ECG abnormalities such as QRS and QT interval prolongation.

Due to the potential for these severe risks, immediate medical attention must be sought following any suspected over-exposure. Management is governed by mandated procedural instructions, as no specific antidote is known to reverse the effects of the drug. Treatment must concentrate on supportive therapy with close medical supervision. Essential procedures include maintaining an adequate airway, oxygenation, and ventilation and instituting cardiac monitoring following an electrocardiogram (ECG). Regulatory reviews also note that pediatric patients may exhibit severe and prolonged lethargy and Extrapyramidal Symptoms (EPS) during an overdose event.

Therapeutic Uses of Irazem

What Irazem Treats: Main Uses and Benefits

Irazem (Aripiprazole) is used across therapeutic domains involving certain distressing symptoms and supports patients during difficult episodes by easing distress. This medication is commonly used across conditions presenting with acute episodes, including schizophrenia, acute manic episodes associated with Bipolar I Disorder, and as an adjunctive treatment for Major Depressive Disorder. It is also applied when appropriate in specific contexts, such as managing severe irritability in Autism Spectrum Disorder and controlling motor and phonic tics related to Tourette Syndrome.

This is relevant when symptoms become temporarily overwhelming, helping to ease the overall symptom burden. It is relevant for managing symptoms that interfere with daily comfort, such as disorganized thinking and extreme shifts in mood or energy.

“It helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.”

By supporting the stabilization of these core symptomatic domains, Irazem assists with maintaining functional stability and may help patients cope more steadily with difficult episodes.

Quick Fact: Symptomatic support for Psychomotor Agitation

Regulatory References

  1. NIH MedlinePlus overview of Aripiprazole

Eligibility and Restrictions for Use

Irazem (Aripiprazole) use is strictly governed by specific regulatory eligibility rules established by government health authorities.

Contraindications and Prohibitions

The medicine is contraindicated for any patient with a known hypersensitivity reaction to aripiprazole or its components. Crucially, the medication is not approved for elderly patients with dementia-related psychosis; official labeling carries a Boxed Warning regarding an increased risk of death associated with this specific use.

Age- and Condition-Specific Eligibility

Adult patients are the primary approved population. For pediatric patients, use is conditionally restricted by minimum age thresholds specific to the indication (e.g., generally ge6 years for some uses). Use is typically not established or approved for children under 6 years of age.

Use is also conditional based on a patient's metabolism; for instance, CYP2D6 poor metabolizers require different usage conditions due to altered drug clearance. Regarding pregnancy, regulatory status notes the risk of neonatal extrapyramidal or withdrawal symptoms with third-trimester exposure, and use during lactation requires careful consideration of the drug's excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Irazem (Aripiprazole) is largely defined by its metabolism through hepatic enzyme systems and its potential for additive pharmacodynamic effects with co-administered substances. All interaction information is derived exclusively from official regulatory labeling.

Pharmacokinetic Interactions (Exposure Modification)

Interactions that alter the plasma exposure of Irazem primarily involve the Cytochrome P450 (CYP) enzymes, specifically CYP3A4 and CYP2D6. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., fluoxetine) results in increased plasma concentrations due to inhibition of drug clearance. Conversely, co-administration with strong CYP3A4 inducers (e.g., carbamazepine) results in a decrease in plasma concentrations as clearance is induced.

Pharmacodynamic and Substance Interactions

Combining Irazem with other medicinal products known to cause CNS depression or products that lower blood pressure (antihypertensive agents) may lead to additive effects, such as intensified somnolence or orthostatic hypotension. The drug is also a transportable P-glycoprotein (P-gp) substrate, suggesting potential changes in systemic absorption with co-administered P-gp inhibitors. Officially, alcohol (ethanol) is documented to exacerbate CNS-related side effects and impair cognitive function.

Population and Administration Constraints

Regulatory documents note that patients identified as CYP2D6 Poor Metabolizers experience a significantly higher exposure to the active compound. For the acute intramuscular injection formulation, a time separation of at least 2 hours between doses is specified.

Mechanism of Action

The action of Irazem is defined by its ability to modulate specific biological targets within defined pathways in the central nervous system. Its mechanistic profile involves interactions with both the dopamine and serotonin receptor systems.

Dopamine System Stabilization

Irazem acts as a Dopamine D2 partial agonist. This interaction results in the occupation and partial stimulation of the D2 receptor, competitively reducing the binding of the brain’s natural dopamine. This singular action profiles Irazem as a Dopamine System Stabilizer (DSS), modulating D2 receptor-mediated signaling toward intermediate activity levels in both high- and low-dopamine environments. The partial agonism results in the controlled adjustment of downstream signaling cascades, influencing the overall set point of pathway activity.

Serotonin Pathway Modulation

Irazem additionally influences Serotonin (5-HT) pathways, specifically through dual action as a 5-HT1A partial agonist and a 5-HT2A antagonist (blocker). The partial agonism at 5-HT1A receptors and the antagonism at 5-HT2A receptors alter the dynamics of signal transduction within relevant pathways. Modification of these molecular steps influences the kinetic properties of neural circuits and their subsequent downstream cascade effects.

Dosage and Administration Information

Irazem (Aripiprazole) is administered via two primary official routes: oral (tablet, orally-disintegrating tablet, and solution) and intramuscular injection (IM). Oral forms are taken once daily and may be consumed without regard to meals. The oral dosage regimen is standardized, typically beginning with a low dose and gradually adjusting over at least two weeks to reach a maintenance range, generally between 10 mg and 15 mg per day, with a maximum dose of 30 mg daily for adult use. Specific, gradual titration schedules are mandated for pediatric patients.

For intermittent administration, Irazem is available as a long-acting injection (LAI) that follows a fixed schedule of once monthly or once every two months. The LAI maintenance dose for the monthly schedule is commonly 400 mg or 300 mg, and is administered into the gluteal or deltoid muscle by a healthcare professional. The LAI powder form requires reconstitution prior to injection. Initiation of the LAI requires a 14-day overlap during which oral Irazem must be taken concurrently with the first injection. The LAI must only be administered intramuscularly and is not approved for intravenous or subcutaneous use.

Mandatory dose adjustments are required for patients who are known CYP2D6 Poor Metabolizers, who must receive a reduction to half the usual oral dose to prevent excessive drug accumulation. Furthermore, official protocols dictate that if an LAI dose is missed beyond a certain time frame, the oral overlap period must be restarted before the next injection is given. The long-acting injection safety and efficacy have not been established for older adults 65 years and over.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 2 Trial Data: Exploring Impact and Adverse Events

Initial studies investigated the compound's link to changes in inflammation. These early-stage studies evaluated whether the compound might be associated with a change in pain reports for people with chronic osteoarthritis.

  • Key Findings:
    • Researchers examined whether a dose-dependent relationship existed between the compound and reported pain levels over 12 weeks.
    • Adverse events were reported by investigators and documented in the study findings. The most commonly reported events included mild headache and digestive discomfort.

Phase 3 Trials: Investigation in Chronic Osteoarthritis

A Phase 3 trial was conducted to assess the compound and its relation to reports of inflammation over time. This trial included a larger group of participants over 52 weeks.

  • Study Population Focus:
    • The study included participants diagnosed with moderate-to-severe chronic osteoarthritis.
    • The study population included participants who had not found satisfactory relief from non-steroidal anti-inflammatory drugs (NSAIDs).
  • Joint Mobility and Function:
    • Researchers assessed physical function and reported joint mobility within the study. Standardized assessment tools were used to measure participant-reported physical function over the study period.
    • One study investigated whether the compound was associated with changes in measures of self-reported quality of life.
  • Combination Therapies:
    • Studies were conducted to evaluate whether the combination of X and Y was associated with different outcomes than X alone. This was explored in a sub-group analysis.

Safety and Exclusion Criteria

The safety profile of the compound was monitored throughout all phases.

  • Hepatic Health:
    • Participants with pre-existing or severe liver impairment were excluded from the studies.
  • Cardiovascular Events:
    • Cardiovascular events were documented and monitored closely by an independent safety committee.
  • Future Research:
    • Initial studies focused primarily on osteoarthritis. Further research may explore other conditions. This area of research continues to be explored.

Key Studies & References Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis - ACR abstract

Frequently Asked Questions (FAQ)

Common questions about Irazem (FAQ)


Q: Can Irazem be used for more than one condition?

Regulatory documents indicate that Irazem is formally approved for use in several conditions. These include major indications such as schizophrenia, bipolar I disorder, and as an add-on treatment for major depressive disorder.


Q: Are the side effects of Irazem usually temporary or long-lasting?

Some common adverse reactions, such as initial dizziness or drowsiness, may decrease over time. However, others, particularly metabolic changes (like high blood sugar) and movement disorders, are recognized as potential long-term risks, and official guidelines recommend monitoring for these changes.


Q: Does Irazem cause weight gain or loss?

Official product information states that medications in this class, including Irazem, have been associated with weight gain. Furthermore, official guidelines note that monitoring for changes in weight is recommended when starting this medication.


Q: Does Irazem interact with common pain relievers like ibuprofen?

Regulatory documents primarily focus on interactions with specific enzyme inhibitors and inducers, CNS depressants, and blood pressure medications. No clinically important interactions between Irazem and common pain relievers like ibuprofen have been formally established in regulatory documents.


Q: Can children or teenagers take Irazem?

Yes, Irazem is approved for specific uses in pediatric patients. The approved age range and indications vary; for example, it may be used for schizophrenia in adolescents aged 13 and older, and for irritability associated with autistic disorder in children aged 6 and older.


Q: What happens if I accidentally miss a dose of Irazem?

If a regular oral dose is missed, regulatory patient instructions advise taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory instructions advise against taking extra or double doses to make up for a missed one.


Q: Do I need a special diet while taking Irazem?

The oral form can be taken without regard to meals. However, because this type of medication can cause metabolic changes like high blood sugar, the official safety information suggests patients be monitored for these changes, which may be relevant to dietary considerations.


Q: Does Irazem affect my ability to drive or operate machinery?

Due to the potential for cognitive and motor impairment (e.g., somnolence, dizziness), regulatory warnings advise caution regarding operating machinery, including driving an automobile.


Q: What kind of medical monitoring is needed while taking Irazem?

Official guidance recommends monitoring for metabolic changes, such as checking fasting blood glucose (sugar) and lipid (fat) levels, at the start of and periodically during treatment.


Q: Are there different strengths or formulations of Irazem?

Yes, Irazem is available in multiple forms, including oral tablets, oral solutions, and injectable forms. The oral tablets come in various strengths, which often range from 2 mg to 30 mg.


Q: Does Irazem interact with grapefruit juice?

Grapefruit is a known strong inhibitor of the CYP3A4 liver enzyme. Official regulatory warnings state that combining Irazem with strong CYP3A4 inhibitors can increase the concentration of the drug in the blood, which is a factor healthcare professionals must consider.


Q: How important is it to take Irazem at the exact same time every day?

The oral formulation of Irazem is administered on a once-a-day schedule. Taking the medication consistently at roughly the same time helps ensure a stable level of the drug is maintained in the body, supporting its effectiveness.


Q: How long can a person safely stay on Irazem treatment?

Regulatory documents note that the medication has demonstrated efficacy in maintenance treatment for conditions like schizophrenia. For patients receiving maintenance therapy, official guidelines recommend periodic reassessment to determine the continued need for treatment.


Q: What should I know about stopping Irazem after long-term use?

Official patient instructions advise against suddenly discontinuing the medication. Gradual dose reduction may be implemented by a healthcare professional to help minimize potential withdrawal-like symptoms.


Q: Are there any withdrawal effects associated with Irazem?

Yes, regulatory information indicates that abruptly stopping the medication may cause a severe reaction in adult patients. Furthermore, there is a known risk of neonatal (newborn) withdrawal symptoms if the medication is taken during the third trimester of pregnancy.


Q: Is it true that Irazem can affect sleep patterns?

Yes, official safety data shows that Irazem can affect sleep. Common adverse reactions reported in regulatory data include both insomnia (difficulty sleeping) and somnolence (drowsiness or sleepiness).


Q: Can Irazem affect mood or cause anxiety?

Official safety documents list anxiety as a potential adverse reaction. Regulatory information also indicates that monitoring for new or worsening depression, anxiety, agitation, or irritability is recommended. The drug is also associated with the emergence of impulse control disorders.


Q: Does Irazem have any effect on kidney or liver function?

Studies on Irazem have specifically examined the pharmacokinetics (how the body handles the drug) in patients with severe hepatic (liver) impairment and renal (kidney) impairment. These results are used to determine if special considerations are needed for these patient groups.


Q: Can Irazem be cut in half or crushed?

The standard conventional tablets are intended to be swallowed whole. The regulatory label does not provide instructions for cutting or crushing them. An orally-disintegrating tablet (ODT) formulation is available for patients who have difficulty swallowing whole tablets.


Q: Can I take my regular vitamins while on Irazem?

Drug interaction warnings primarily focus on prescription medications that are strong inhibitors or inducers of certain liver enzymes. Caution is advised regarding combining Irazem with strong inducers or inhibitors of certain liver enzymes; consulting product labeling is the safest approach.


Q: Is Irazem a controlled substance?

No, according to official regulatory documentation, Irazem (Aripiprazole) is not classified as a controlled substance under the Controlled Substances Act.


Q: What are the signs of an allergic reaction to Irazem?

Official patient information advises seeking immediate medical attention if signs of a severe allergic reaction occur. These signs may include skin rash, itching, hives, or swelling of the face, lips, tongue, or throat.


Q: Does Irazem contain lactose or gluten?

Regulatory information indicates that the oral tablets often contain lactose monohydrate as an inactive ingredient. The orally-disintegrating tablet (ODT) formulation also contains phenylalanine, which is important for individuals with certain metabolic conditions.


Q: Are there any major studies that support the use of Irazem?

Yes, official regulatory approval is based on extensive clinical data. The product label includes sections detailing major clinical studies, such as long-term maintenance trials, that support its approved indications.


Q: Can Irazem be taken with or without food?

According to the official prescribing information, the oral forms of Irazem can be administered to the patient without regard to whether or not they have had a meal.


Q: How quickly should I start feeling a difference after taking Irazem?

Achieving the full benefit of Irazem can take time. Regulatory guidelines suggest that dose adjustments for the oral form should generally not be made sooner than two weeks, as this time is needed to reach a stable concentration of the drug in the body.


Q: What is the typical timeframe for Irazem to fully take effect?

Because the dose may be gradually adjusted over a period of at least two weeks to reach a maintenance range, and time is required to reach steady drug levels, the full therapeutic effect is typically observed over a period of several weeks.

How should Irazem be stored and disposed of?

Irazem must be stored according to regulatory specifications to ensure product stability and safety.

Storage Requirements

  • Temperature: Oral forms (tablets, solution) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are allowed between 15 C and 30 C.
  • Protection: The medication must be kept in the original container and protected from both light and moisture.
  • Child Safety: All forms of Irazem should be stored out of the sight and reach of children.

Stability and Handling

  • IM Injection: The prepared long-acting injection suspension must be used immediately, or stored at or below 25 C for a limited time (e.g., up to 4 hours in the vial).

Disposal Instructions

  • Disposal Method: Unused or expired medication should be discarded via an authorized drug take-back program.
  • Environmental Restriction: Irazem must not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Irazem found in:

A-Z Index: